The escalating prevalence of neurological disorders presents a growing challenge for healthcare, particularly in an aging population. Early diagnosis is crucial for effective treatment, but the mildness of initial symptoms and the absence of accessible monitoring tools can result in delays. Additionally, existing biomarkers lack objectivity, detailed insights, and reproducibility, impeding progress in diagnosis, treatment, and drug development.
